Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Oncocyte Corp (OCX)

Oncocyte Corp (OCX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 90,789
  • Shares Outstanding, K 67,251
  • Annual Sales, $ 0 K
  • Annual Income, $ -22,430 K
  • 60-Month Beta 2.64
  • Price/Sales 499.40
  • Price/Cash Flow N/A
  • Price/Book 2.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.11
  • Number of Estimates 1
  • High Estimate -0.11
  • Low Estimate -0.11
  • Prior Year -0.10
  • Growth Rate Est. (year over year) -10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2000 +10.00%
on 07/08/20
1.5900 -16.98%
on 07/06/20
-0.2300 (-14.84%)
since 07/02/20
3-Month
1.2000 +10.00%
on 07/08/20
3.5100 -62.39%
on 06/25/20
-1.2100 (-47.83%)
since 05/01/20
52-Week
1.2000 +10.00%
on 07/08/20
3.5100 -62.39%
on 06/25/20
-0.3500 (-20.96%)
since 08/02/19

Most Recent Stories

More News
OncoCyte (OCX) Reports Q2 Loss, Tops Revenue Estimates

OncoCyte (OCX) delivered earnings and revenue surprises of -27.27% and 257.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

OCX : 1.3100 (-2.96%)
Oncocyte to Report Second Quarter 2020 Financial Results on Wednesday, July 29

Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that...

OCX : 1.3100 (-2.96%)
Oncocyte Announces Distribution Agreement with ProGenetics Ltd, Expanding Commercial Availability of DetermaRx(TM) to Israel

Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that...

OCX : 1.3100 (-2.96%)
Oncocyte Provides an Update on the Rapid Growth of DetermaRx(TM) Physician Adoption and Testing Volume

Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today provided an update...

OCX : 1.3100 (-2.96%)
Notable Appoints Biotech Veteran Joseph Wagner PhD as Chief Scientific Officer

Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, announced today that Joseph Wagner, PhD, has joined the company as Chief Scientific...

OCX : 1.3100 (-2.96%)
AgeX Therapeutics, Inc. Appoints Andrea Park as Chief Financial Officer

AgeX Therapeutics , Inc. ("AgeX": NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that Andrea Park has been appointed Chief Financial...

AST : 0.94 (unch)
OCX : 1.3100 (-2.96%)
Oncocyte to Report First Quarter 2020 Financial Results on Tuesday, May 12

Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that...

OCX : 1.3100 (-2.96%)
Oncocyte Announces Final Medicare LCD from Palmetto for DetermaRx(TM)

Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that...

OCX : 1.3100 (-2.96%)
Oncocyte Announces $10.7 Million Registered Offering

Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that...

OCX : 1.3100 (-2.96%)
Lineage Cell Therapeutics Conducts Sale of Shares in OncoCyte Corporation

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced the pricing of the sale of 1,672,689...

OCX : 1.3100 (-2.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Trade OCX with:

Business Summary

OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California.

See More

Key Turning Points

2nd Resistance Point 1.5033
1st Resistance Point 1.4267
Last Price 1.3100
1st Support Level 1.3067
2nd Support Level 1.2633

See More

52-Week High 3.5100
Fibonacci 61.8% 2.6276
Fibonacci 50% 2.3550
Fibonacci 38.2% 2.0824
Last Price 1.3100
52-Week Low 1.2000

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar